Clinical trials: Demyelinating Disorder
Relapsing-remitting Multiple Sclerosis
A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis
The aim of this protocol is to find out about the safety and effectiveness of M2951 in participants with relapsing multiple sclerosis.
- Trial name
- NCT02975349
- Testing
- Evobrutinib, Tecfidera
- Where
- 56 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 267 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Multiple Sclerosis
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.
- Trial name
- NCT02576717
- Testing
- RPC1063
- Where
- 175 sites in United States, Belarus and 24 more
- Volunteers
- 2,494 people
- Sponsor
- Celgene
Radiologically Isolated Syndrome, Multiple Sclerosis
Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.
This is a multicenter, randomized, double-blind, placebo-controlled, Phase 4 study in which eligible patients with RADIOLOGICALLY ISOLATED SYNDROME (RIS) (as defined by meeting 2017 McDonald criteria for DIS) will be randomized…
- Trial name
- CELLO (NCT04877457)
- Testing
- Ocrelizumab
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- Yale University
Multiple Sclerosis
Integrating Caregiver Support Into MS Care
With loss of mobility in multiple sclerosis (MS) comes an increase in amount and types of caregiver assistance, with a concomitant increase in burden for the caregiver.
- Trial name
- NCT02835677
- Testing
- Behavioral
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- VA Office of Research and Development
Neuromyelitis Optica Spectrum Disorder, NMOSD
A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention
Objective of the trial is to describe the efficacy and safety of satralizumab in patients with aquaporin-4 (AQP4) antibody seropositive NMOSD, either treatment naive or inadequate responders to previous treatment with rituximab…
- Trial name
- SAkuraBonsai (NCT05269667)
- Testing
- Satralizumab 120 mg
- Where
- 3 sites in United States, South Korea and 1 more
- Volunteers
- 4 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
Prospective Randomized Endovascular Therapy in Multiple Sclerosis - PREMiSE
The Departments of Neurology and Neurosurgery are conducting this research study to evaluate the safety and effectiveness of intravascular angioplasty for the treatment of venous narrowing in the treatment of Multiple Sclerosis…
- Trial name
- PREMiSE (NCT01450072)
- Testing
- Selective Venography followed by therapeutic balloon angioplasty, Control arm
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- State University of New York at Buffalo
AMN, AMN Gene Mutation
A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)
This is a Phase 1/2 randomized, blinded, dose-escalation study to evaluate the safety and efficacy of intrathecal (IT) administration of SBT101, a recombinant adeno-associated virus serotype 9 (AAV9) containing a functional copy…
- Conditions
- AMN, AMN Gene Mutation, X-ALD
- Trial name
- PROPEL (NCT05394064)
- Testing
- SBT101 Treatment
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 9 people
- Sponsor
- SwanBio Therapeutics, Inc.
Relapsing Remitting Multiple Sclerosis
Fingolimod Effect on Cytokine and Chemokine Levels
The main purpose of this study was to measure the serum levels of cytokines and chemokines that are known to increase during multiple sclerosis relapses.
- Trial name
- NCT02373098
- Testing
- Fingolimod 0.5 mg
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)
The primary objective of Part 1 of this study is to evaluate the effects of BIIB033 versus placebo on disability improvement over 72 weeks.
- Trial name
- AFFINITY (NCT03222973)
- Testing
- BIIB033 (opicinumab)
- Where
- 159 sites in United States, Australia and 13 more
- Volunteers
- 263 people
- Sponsor
- Biogen
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the safety, tolerability and activity of ibudilast administered twice daily over a 96 week period in subjects with…
- Trial name
- NCT01982942
- Testing
- ibudilast
- Where
- 28 sites in United States
- Volunteers
- 255 people
- Sponsor
- MediciNova
Cerebral Adrenoleukodystrophy (CALD)
A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
The purpose of this study is to evaluate the efficacy and safety of Lenti-D Drug Product (also known as elivaldogene autotemcel or Skysona, hereafter referred to as eli-cel) after myeloablative conditioning with busulfan and…
- Trial name
- NCT03852498
- Testing
- Lenti-D
- Where
- 8 sites in United States, France and 4 more
- Volunteers
- 35 people
- Sponsor
- Genetix Biotherapeutics Inc.
Multiple Sclerosis, Spasticity, Muscle
A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS
Spasticity is a common complication in MS and occurs in up to 84% of patients. The main sign of spasticity is resistance to passive limb movement characterized by increased resistance to stretching, clonus, and exaggerated deep…
- Trial name
- OS440-3005 (NCT03319732)
- Testing
- Arbaclofen
- Where
- United States
- Volunteers
- 323 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Relapsing-Remitting Multiple Sclerosis
Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
The primary objective of this study is to assess the effect of natalizumab compared to fingolimod on the evolution of new on-treatment T1-gadolinium-enhancing (Gd+) lesions to persistent black holes (PBH) over 52 weeks.
- Trial name
- REVEAL (NCT02342704)
- Testing
- natalizumab, fingolimod
- Where
- 42 sites in United States, Australia and 7 more
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Biogen
Multiple Sclerosis
Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis
The purpose of this study is to determine if the study drug is effective and safe in the treatment of Multiple Sclerosis (MS) in patients of Chinese origin.
- Trial name
- NCT00370071
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 3 sites in China
- Volunteers
- 39 people
- Sponsor
- Bayer
Multiple Sclerosis
Comparison of Robot-Assisted Gait Training and Conventional Therapy in Multiple Sclerosis Patients
The aim of this study is to compare conventional neurorehabilitation with robot-assisted gait training program in terms of fatigue, anxiety, depression and quality of life.
- Trial name
- NCT03801473
- Testing
- robot assisted gait therapy, Conventional rehabilitation
- Where
- Turkey (Türkiye)
- Volunteers
- 42 people
- Sponsor
- Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Multiple Sclerosis (MS)
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis
The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with progressive Multiple Sclerosis (PMS).
- Trial name
- NCT03737812
- Testing
- elezanumab
- Where
- 37 sites in United States, Canada
- Volunteers
- 123 people
- Sponsor
- AbbVie
Multiple Sclerosis
A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly
The aim of this multicentre, randomised, double-blind, placebo-controlled study is to evaluate the efficacy and safety of supplementary treatment with cholecalciferol (vitamin D3) in subjects with relapsing multiple sclerosis (R…
- Trial name
- CHOLINE (NCT01198132)
- Testing
- Cholecalciferol (Vitamin D3), Rebif
- Where
- France
- Volunteers
- 129 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Activity and Balanced Eating to Reduce Comorbidities and Symptoms of MS
Multiple sclerosis (MS) is the leading cause of irreversible neurological disability among young women and the second leading cause of disability among young men in the U.S.
- Trial name
- ABC's of MS (NCT03808545)
- Testing
- Behavioral Intervention for Physical Activity in Multiple Sclerosis (BIPAMS), BIPAMS + Diet
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Alabama at Birmingham
Multiple Sclerosis, Neurological Disorder
Cognitive Remediation Augmented With Transcranial Direct Current Stimulation (tDCS)
The proposed study will test the feasibility and tolerability of transcranial direct current stimulation (tDCS) added to a cognitive remediation program in n=100 adults.
- Trial name
- NCT03049969
- Testing
- tDCS stimulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- NYU Langone Health
Multiple Sclerosis, Clinically Isolated Syndrome
A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab
This study will evaluate the pharmacokinetics of ocrelizumab in the breastmilk of lactating women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally approved indications] treated with…
- Trial name
- SOPRANINO (NCT04998851)
- Testing
- Ocrelizumab
- Where
- 8 sites in United States, Spain and 1 more
- Volunteers
- 26 people
- Sponsor
- Hoffmann-La Roche